Travis Alvin Thompson sold $157k of BCYC
CHIEF ACCOUNTING OFFICER at BICYCLE THERAPEUTICS PLC. 6,256 shares at an average of $25.11, traded Nov 11, 2024, filed Nov 13, 2024.
Score components
- +15RoleOfficer
- +11Trade size$157k at market
- +10Share of holdings soldSold 26% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -40.5%, 3m -46.9%, 6m -65.5%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-24-026758, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 11, 2024 | MOption exercise Ordinary Shares10b5-1 | +1,312 | $1.87 | $2,453 | 24,234 | Nov 13, 2024 |
| Nov 11, 2024 | SOpen-market sale Ordinary Shares10b5-1 | -1,312 | $25.05 | $33k | 22,922 | Nov 13, 2024 |
| Nov 11, 2024 | MOption exercise Ordinary Shares10b5-1 | +154 | $8.21 | $1,264 | 23,076 | Nov 13, 2024 |
| Nov 11, 2024 | SOpen-market sale Ordinary Shares10b5-1 | -154 | $25.01 | $3,852 | 22,922 | Nov 13, 2024 |
| Nov 11, 2024 | MOption exercise Ordinary Shares10b5-1 | +1,109 | $9.82 | $11k | 24,031 | Nov 13, 2024 |
| Nov 11, 2024 | SOpen-market sale Ordinary Shares10b5-1 | -1,109 | $25.05 | $28k | 22,922 | Nov 13, 2024 |
| Nov 11, 2024 | SOpen-market sale Ordinary Shares10b5-1 | -3,241 | $25.21 | $82k | 19,681 | Nov 13, 2024 |
| Nov 11, 2024 | SOpen-market sale Ordinary Shares10b5-1 | -209 | $24.77 | $5,177 | 19,472 | Nov 13, 2024 |
| Nov 11, 2024 | SOpen-market sale Ordinary Shares10b5-1 | -231 | $24.82 | $5,733 | 19,241 | Nov 13, 2024 |
| Nov 11, 2024 | MOption exercise Employee Stock Option (right to buy)derivative10b5-1 | -1,312 | $0.00 | $0 | 2,617 | Nov 13, 2024 |
| Nov 11, 2024 | MOption exercise Employee Stock Option (right to buy)derivative10b5-1 | -154 | $0.00 | $0 | 302 | Nov 13, 2024 |
| Nov 11, 2024 | MOption exercise Employee Stock Option (right to buy)derivative10b5-1 | -1,109 | $0.00 | $0 | 12,954 | Nov 13, 2024 |
Related signals
Other insiders at BICYCLE THERAPEUTICS PLC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | BICYCLE THERAPEUTICS PLC | Jennifer Scott Perry Chief Operating Officer | $1,339 356 shares | -0% | |
| 30Weak | BICYCLE THERAPEUTICS PLC | Michael Skynner CHIEF SCIENTIFIC OFFICER | $8,534 2,445 shares | -2% | |
| 45Moderate | BICYCLE THERAPEUTICS PLC | Kevin Lee CHIEF EXECUTIVE OFFICER | $27k 7,805 shares | -1% | |
| 37Weak | BICYCLE THERAPEUTICS PLC | Travis Alvin Thompson Chief Financial Officer | $3,381 972 shares | -1% | |
| 30Weak | BICYCLE THERAPEUTICS PLC | Michael Charles Ferguson Hannay CHIEF PROD & SUPPLY CHAIN OFF | $6,319 1,814 shares | -2% | |
| 35Weak | BICYCLE THERAPEUTICS PLC | Robert Charles Swanton director | $12k 3,431 shares | -18% | |
| 15Weak | BICYCLE THERAPEUTICS PLC | Jennifer Scott Perry Chief Operating Officer | $5,313 1,500 shares | -2% | |
| 30Weak | BICYCLE THERAPEUTICS PLC | Travis Alvin Thompson CHIEF ACCOUNTING OFFICER | $2,500 319 shares | -1% | |
| 30Weak | BICYCLE THERAPEUTICS PLC | Michael Charles Ferguson Hannay CHIEF PROD & SUPPLY CHAIN OFF | $5,735 733 shares | -1% | |
| 35Weak | BICYCLE THERAPEUTICS PLC | Alistair Milnes CHIEF OPERATING OFFICER | $17k 2,171 shares | -2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.